Back to Journals » OncoTargets and Therapy » Volume 11
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
14,548 | Dovepress* | 11,458+ | 1,356 | 12,814 | |
PubMed Central* | 3,090 | 901 | 3,991 | ||
Totals | 14,548 | 2,257 | 16,805 | ||
*Since 22 November 2018 |
View citations on PubMed and Google Scholar